Drugs / mecbotamab vedotin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03425279 | Feb 2018 → Jan 2025 | myxofibrosarcoma, undifferentiated pleomorphic sarcoma | BioAtla, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04918186 | May 2022 → Dec 2026 expected | ovarian cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT04681131 | Mar 2021 → Jul 2025 | non-small cell lung carcinoma | BioAtla, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mecbotamab vedotin | “mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗ |
| Known as | BA3011 | “mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗2“BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT04681131 ↗ |
| Known as | CAB-AXL-ADC | “mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗ |
| Known as | Mecbotamab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095312 ↗ |
| Known as | Mecbotamab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095312 ↗ |
| Modality | Other / unclassified | “a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗ |
| Target | AXL | “AXL-targeted” NCT03425279 ↗ |